Introduction {#s1}
============

Hypertrophic cardiomyopathy (HCM) has been recognized for more than fifty years, with first pathological description published in 1958, followed by the first clinical report in the early 1960s \[[@R1]\]. Since then, clinical, biochemical, pathologic, and genetic studies have made enormous progress to better understand this inherited disease. However, this information has not yet been translated into practical information necessary for the prevention or treatment of HCM. This is in part because of the unexpected heterogeneity and complexity in phenotypic presentations with underlying genetic causes of HCM. To date, over 1,500 mutations in at least 20 genes encoding the myofilaments of the sarcomere or Z-disc have been identified to be causative or associated with HCM. This polygenetic feature of HCM makes a homogenous study population challenging to identify given the large numbers required for successful human clinical trials \[[@R2]\]. Controlled prospective studies are necessary to identify pre-clinical signs of disease in human HCM patients, but such studies are complicated, expensive, and require lengthy periods of longitudinal follow-up. Mouse models of HCM overcome some of these challenges to advance our understanding of HCM. However, they have other limitations that prevent direct translation to human medicine because of intrinsic differences in their cardiac physiology, response to cardiac stress, hemodynamics, and the inherent resistance of rodent hearts to arrhythmia due in part to the small size and rapid kinetics of their hearts. The need for more direct translational models, particularly large-animal models, of HCM is clearly identified. 

HCM is also known to be the most common inherited cardiac disease in the domestic cats \[[@R3]\]. Large numbers of biochemical, genetic, and clinical studies have been conducted evaluating feline HCM over the last few decades. These studies revealed that feline HCM follows incredibly similar clinical and pathological presentations as human HCM, and shows promise to serve as an animal model of human HCM. At least two cat breeds share genetic similarity to human HCM cases where mutations in myosin binding protein C (MYBPC) have been reported as a major contributor to development of HCM \[[@R4],[@R5]\]. However, a majority of feline HCM cases are of yet unknown genetic etiology and other undiscovered mutations are likely involved in developing feline HCM. Recently a unique large animal model of HCM is observed in the rhesus macaque, and pedigree investigation has revealed that this condition is also familial and likely heritable \[[@R6],[@R7]\]. Once clinical, molecular, pathologic, and genetic studies are completed, this may serve as an excellent non-human primate model of HCM and further our ability to perform meaningful research into various aspects of HCM including novel therapeutics. 

In this review, current knowledge and understanding of pathophysiological, clinical, diagnostic, and genetic aspects of human HCM are reviewed. Furthermore, translational and comparative models of naturally occurring or transgenic HCM in other species such rodents, cats, and non-human primates are summarized and discussed to identify the potentials for propelling further translational investigations of HCM. 

General Pathophysiology of Hypertrophic Cardiomyopathy  {#s2}
=======================================================

Hypertrophied myocytes with disorganized sarcomeric alignment are hallmark histopathological changes in human HCM ([Figure 1](#F1){ref-type="fig"}) \[[@R8]\]. The hypertrophied myocytes may possess unusually shaped nuclei and chaotic myofibril alignment \[[@R8]\]. They also frequently have abnormalities in the coronary arteriolar walls \[[@R9]\], elongation or malformation of mitral valve leaflets \[[@R10]\], and presence of myocardial fibrosis, leading to further functional abnormalities of the heart \[[@R11]\]. 

Primary components of the functional disturbances observed with HCM are reduced stroke volume with diastolic dysfunction, reduced chamber size, and decreased compliance of the left ventricle (LV) \[[@R12]\]. Stroke volume can be even further reduced by the presence of left ventricular outflow obstruction (LVOTO). LVOTO most commonly develops secondary to systolic anterior motion (SAM) of the mitral valve generating mechanical interference along the pathway of the LV outflow tract. This causes increased pressure in the LV lumen and elevated flow velocity through the LV outflow tract. Elevated LV outflow tract velocity can further worsen SAM and lead to the development of mitral regurgitation ([Figure 2](#F2){ref-type="fig"}). LVOTO can also occur at the mid-cavity or apex of the LV lumen resulting from symmetric or asymmetric hypertrophy of LV anterior and/or posterior walls \[[@R13]\]. Therefore, the degree of reduced stroke volume due to HCM may vary depending on the degrees of diastolic dysfunction, myocyte hypertrophy, LVOTO, mitral regurgitation and cardiac systolic dysfunction. Additionally, it is important to note that LVOTO may be dynamic and often dependent on physiological state, making its presence more common and more severe with exercise or catecholamine stimulation \[[@R14],[@R15]\]. 

Hypertrophic Cardiomyopathy in Humans {#s3}
=====================================

A previous population analysis reported in 1995 estimated the prevalence of human HCM to be at least 1 in 500 adults \[[@R2],[@R16]\]. HCM is identified across all ethnic groups as well as in both sexes \[[@R17]\]. The overall prevalence of HCM is lower in African-American patients compared to white patients, but sudden death due to HCM is more frequent in African-Americans in the United States \[[@R18],[@R19]\]. Male patients are overrepresented to female patients, while female patients tend to be diagnosed with HCM at older ages with symptoms of heart failure (HF) \[[@R18]-[@R20]\]. However, the overall prevalence of HCM may be underestimated since many HCM individuals do not develop any obvious clinical symptoms during their life spans \[[@R21]\]. Asymptomatic HCM is frequently diagnosed during family screening for HCM or diagnostic examination for other cardiovascular diseases on electrocardiography (ECG), echocardiography, or cardiovascular magnetic resonance images (CMR) \[[@R2]\]. 

Clinical Manifestations in Humans {#s3a}
---------------------------------

HCM is associated with a broad spectrum of clinical manifestations from no symptoms with normal lifestyle and life span to serious clinical complications \[[@R21],[@R22]\]. The common clinical symptoms related to HCM include sudden death (SD), heart failure (HF), and atrial fibrillation (AF). Age is a key factor that impacts the likelihood of developing the clinical symptoms, where SD events are most common in young patients, while HF and AF are more common in middle-aged to elderly patients \[[@R23]\]. In fact, HCM remains the most common cause of athletic field deaths in high school and college age students in the United States \[[@R24]\]. These SD events may occur without warning during physical activity, and are thought to be primarily due to development of ventricular tachycardia and fibrillation \[[@R22]\]. 

The clinical signs of HF in HCM patients include difficulty breathing, which is often associated with the presence of diastolic dysfunction, LVOTO, mitral regurgitation, and systolic dysfunction \[[@R21],[@R22]\]. About one-third of HCM patients with HF do not have significant LVOTO at rest, but develop LVOTO during exercise or under stress \[[@R25]\]. Exercise induced LVOTO identifies patients possessing higher risk of HF development, and thus therapeutic intervention before developing HF symptoms may become indicated. 

Approximately 25 percent of HCM patients develop atrial fibrillation (AF) during their clinical courses and thus AF is most commonly identified clinical symptom of HCM \[[@R26]\]. Development of AF due to HCM is associated with increasing age, greater left atrial size, and impaired left atrial ejection fraction \[[@R27]\]. Manifestation of AF itself may not result in serious clinical conditions, although it is often associated with the presence of LVOTO and progressive HF \[[@R28]\]. In addition, AF due to HCM is a risk factor for developing thromboembolic disease (e.g., stroke). Interestingly, no significant relationship in human HCM has been reported between AF and SD \[[@R26]\]. 

Genetics of HCM in Humans {#s3b}
-------------------------

HCM in humans is an inherited disease with an autosomal dominant pattern and incomplete penetrance \[[@R29]\]. Since the first sarcomeric gene mutation associated with HCM was identified approximately 25 years ago, more than 1,500 mutations across at least 20 genes encoding myofilament proteins have been identified and linked to human HCM \[[@R2],[@R29]\]. Approximately 70 percent of human HCM cases are primarily associated with mutations in two major genes: beta-myosin heavy chain (*MYH*) and myosin-binding protein C (*MYBPC*) \[[@R28]\]. These proteins are the major components of the thick filament of sarcomeres providing structural support and regulating muscle contractions. Notably, HCM patients possessing a mutation in one of these two genes are observed to have increased severity of HCM compared to HCM patients with mutations in other genes ([Table 1](#T1){ref-type="table"}) \[[@R30]\]. Despite these advancements in understanding the genetic etiology of HCM in many cases, this genetic data has not altered the treatments or provided enough information to prognosticate or prevent HCM in a clinical setting. This is mainly due to the vast devastating genetic heterogeneity of this condition, where various mutations are identified within the *MYH* and *MYBPC* genes \[[@R29]\]. For example, some sarcomeric mutations in these major genes don't cause significant left ventricular hypertrophy (LVH), but rather lead patients to develop other clinical manifestations of HCM including diastolic dysfunction, AF, and SD \[[@R31]\]. Other studies have shown that different mutations in these genes may result in different morphology of LVH \[[@R48]\]. In addition, about 3 to 5 percent of HCM affected humans have more than one HCM-associated mutation and the clinical symptoms in patients with multiple mutations are generally more severe and confer greater risk of SD \[[@R32]\]. 

Genes encoding cardiac troponins (*TNNI3*, *TNNT2*, *TNNC1*) are found to play a key role in developing HCM in humans ([Table 1](#T1){ref-type="table"}). The cardiac troponin is composed of three subunits including cardiac troponin C (cTnC), cardiac troponin I (cTnI), and cardiac troponin T (cTnT). Among these genes, *TNNI3* is specific to cTnI and a single protein isoform has been identified, while *TNNT2* is specific to cTnT and twelve different isoforms have been described \[[@R33]\]. Previous studies noted that several missense mutations in *TNNI3* and *TNNT2* were found to be associated with developing varied clinical manifestations of HCM in humans. For example, *TNNI3* gene mutation (R145G missense mutation) is shown to be associated with developing significant LVH \[[@R34]\], while *TNNT2* gene mutation (179N missense mutation) was reported to be associated with higher incidence of SD and minimal LVH \[[@R35]\]. 

Genes encoding proteins within the Z-disc and M-band are also known to have mutations associated with human HCM. These genetic variants were identified within the genes encoding titin (*TTN*), muscle LIM protein (CSRP), myozenin 2 (*MYOZ2*) and telethonin (*TCAP*) \[[@R36]-[@R40]\]. These mutations in Z-disc result in alterations of protein-protein interactions leading to excessive response to mechanical load and ultimately result in LVH. Similarly, a mutation in myomesin as an M-band protein has been identified in human HCM patients \[[@R41]\].  

Although many mutations have been reported for HCM in humans, the association of specific mutations with the clinical characteristics of HCM is still controversial because of genotypic and phenotypic heterogeneities. These mutations cannot be routinely used to prognosticate human HCM as large cohorts of a single mutation are infrequent and thus comparing clinical outcomes by mutation is incredibly challenging \[[@R42]\]. Additionally, the presence of modifier genes that can modulate the phenotype of HCM, renders genotype-based prognostication even more challenging. For example, a few genetic variants of the angiotensin II type 2 receptor gene were described to be associated with the severity of LVH in human HCM patients with sarcomeric gene mutations \[[@R43]\]. Another study evaluated the calmodulin (*CALM3*) gene and reported a mutation that modifies HCM expression by altering an intracellular calcium sensitization in human HCM \[[@R44]\]. 

Diagnosis of HCM in Humans  {#s3c}
---------------------------

Electrocardiographic (ECG) abnormalities are frequently seen, occurring in approximately 95 percent of human HCM in one study \[[@R45]\]. Typical ECG findings in humans with HCM include increased precordial voltages and ST segment and T wave abnormalities with LVH, prominent deep and narrow Q-waves with asymmetric LVH, and p-wave abnormalities (P-mitrale) with left atrial enlargement \[[@R46]\]. These ECG abnormalities are not specific to HCM, and further evaluations are necessary to rule out other diseases resulting in the similar ECG abnormalities (e.g., myocardial infarction). 

Imaging plays a key role in diagnosing HCM. The two imaging modalities frequently used to diagnose HCM in humans include echocardiography and cardiovascular magnetic resonance images (CMR). HCM is typically diagnosed by two-dimensional (2D) echocardiography with LV wall thickness (more than 15 mm in humans) in diastole, after excluding other possible causes of LVH, such as aortic stenosis, systemic hypertension, infiltrative disease, storage disorders, and athlete's heart (3) \[[@R22]\]. 2D echocardiography also identifies the pattern and location of LVH. The common locations for LVH described on 2D echocardiography include basal anterior septum, anterior free wall, and the posterior septum at the mid-LV level \[[@R47]\]. Two-dimensional echocardiography can be used to assess the outflow tract and valves for regurgitations or SAM under various conditions such as exercise, Valsalva maneuver, and isoproterenol administration. Using continuous-wave, pulsed-wave, and color-Doppler techniques, echocardiography can determine the LV outflow gradients to determine the presence of LVOTO before and after these physiologic manipulations. CMR can provide additional information about cardiac structure. CMR may identify the LVH in segments not visualized well with echocardiography and further characterize structural abnormalities of the mitral valve or papillary muscles. CMR combined with late gadolinium enhancement can also be used to quantify myocardial fibrosis which is reported to be a predictor of SD \[[@R48]\]. 

Cardiac biomarkers have been frequently utilized to assess the degree and severity of human HCM. Several studies showed that elevated serum cTnT level was associated with degree of LVH and diastolic dysfunction, increased risk of developing SD, HF, AF, and thromboembolic disease (e.g., stroke) in HCM patients \[[@R49]\]. cTnI is also found to be associated with the degree of LVH and diastolic dysfunction due to HCM \[[@R50]\]. In addition, the recently developed highly sensitive troponin (hs-Tn) assays have significantly higher sensitivity and specificity for diagnosing HCM and elevated hs-Tn level is associated with a greater risk of developing complications such as SD and HF \[[@R50]\]. B-type natriuretic peptide (BNP) concentration has also been used for diagnosing and prognosticating HF due to HCM, and the degree of LVH is also known to be independently associated with BNP level \[[@R51]\]. BNP level is significantly elevated in human HCM patients with HF. BNP level is shown to trend higher as the severity of HF increases \[[@R52]\]. However, there is significant overlap of serum BNP concentrations in HCM patients with HF and without HF \[[@R52]\]. Therefore, diagnosing the presence and degree of HF in patients with HCM based just solely on the BNP levels may have limited utility and must always be interpreted in concert with other diagnostic tests. 

There are many laboratories offering screening to genotype patients for known mutations associated with HCM. However, using single mutations to predict clinical characteristics, prognosticate, or choose an appropriate treatment option is unreliable for individual patients due to the significant heterogeneity of HCM. Currently, the most useful application for genetic testing is for family screenings, particularly when individuals have relatives previously diagnosed with HCM \[[@R28]\]. 

Hypertrophic Cardiomyopathy in Animal Models  {#s4}
=============================================

Molecular and biochemical effects of the individual mutations associated with HCM have been extensively investigated *in vitro* where the function of altered proteins can be directly evaluated. Proving the mutation results in clinical manifestation also requires studies *in vivo* with extensive pedigree analysis of HCM affected families or with studies using an animal model. Developing an animal HCM model provides considerable data in relatively short periods of time, especially regarding genotype and phenotype interactions as well as disease progression. With this purpose in mind, multiple animal models of HCM were developed over time \[[@R53]\]. 

Hypertrophic Cardiomyopathy in Mouse Models  {#s5}
============================================

Mouse models have been utilized commonly to study human cardiac disease, because 99 percent of human genes have direct murine orthologues and mice have high reproductive efficiency and short life spans \[[@R54]\]. In 1996, the first mouse model of HCM with a *MYH7* mutation was created and they provided a great deal of information regarding the natural history of *MYH7* associated HCM \[[@R55]\]. In 1999, another lineage of mice with HCM and an alpha-*MYH* mutation was created \[[@R56]\]. The heterozygous mice with this mutation had the typical features of HCM including LVH, but homozygous animals died shortly after birth. Since then, mouse models with nearly every known human gene mutation have been created. 

For mutations in the *TNNT2* and *TNNI3* genes, transgenic mouse models were created and morphological and functional changes with these mutations were investigated. For example, I79N missense mutation in the *TNNT2* was reported to be associated with higher risk of SD without any significant LVH, \[[@R35]\] while the transgenic mice with this mutation developed higher contractility and diastolic dysfunction of the heart, potentially explaining the mortality especially during exercise \[[@R57]\]. Transgenic mice with *TNNI3* mutation also developed LVH due to compensatory mechanisms showing that this mutation caused higher energy to create a contraction force and reduced diastolic function as a result of prolonged calcium ion and force transitions \[[@R36]\]. 

Using transgenic mouse models allows us to investigate genetic and phenotypic interactions in relatively a short period of time \[[@R58],[@R59]\]. However, mice have significantly different contractile function from humans, mainly due to their small size. In addition, the murine heart is composed mainly of alpha-myosin, while the human heart consists mainly of beta-myosin \[[@R53],[@R54]\]. Due to these differences, the mouse models typically do not represent all aspects of human HCM making the direct translation of novel therapies from mouse to human incredibly challenging \[[@R58]\]. Therefore, information obtained from transgenic mouse models must be interpreted carefully, and need to be extended into larger animal models and eventually into humans to fully understand the genetic and phenotypic interactions of HCM. 

Hypertrophic Cardiomyopathy in Feline Models {#s6}
============================================

HCM is also the most common inherited cardiac disease in the domestic cat with a recent estimate as high as 1 in 7 (14.7 percent of a general population of 780 cats screened once by echocardiogram) \[[@R60]\]. Approximately 57 percent of feline idiopathic cardiomyopathies are hypertrophic \[[@R61],[@R62]\]. In 1970, a study evaluated the postmortem characteristics of feline cardiac disease that leads to congestive HF and identified feline HCM as analogous to the human form of this disease \[[@R63]\]. Since then, abundant research characterizing the pathologic, genetic, biochemical, and echocardiographic features of this condition in cats has been published. Histopathology of feline HCM is similar to that of human HCM, characterized by disorganized arrangement of myocytes and abnormal intramural coronary arterial walls ([Figure 1](#F1){ref-type="fig"}) \[[@R64]\]. As in human HCM, clinical manifestations of feline HCM vary from asymptomatic to serious complications such as SD, HF, and thromboembolic diseases. There are, however, some marked differences in the clinical manifestations of HCM between humans and cats. In human HCM, clinical symptoms have a broad spectrum, and often occur as an asymptomatic form. The most common disease manifestation of human HCM is SD in young adults and HF in middle-aged to elderly patients \[[@R16],[@R17]\]. In contrast, feline HCM is most commonly associated with congestive heart failure (CHF) characterized pulmonary edema and/or pleural effusion \[[@R65]\]. HF. In one clinical study of cats with respiratory distress, more than 50 percent of those diagnosed with CHF had HCM \[[@R66]\]. This high prevalence of CHF in cats with HCM might be associated with the significant phenotypic and genotypic differences between humans and cats. Another possibility is that feline HCM is more prevalent in apparently healthy patients and we simply do not see these healthy cats in veterinary hospitals due to a lack of standardized screening protocols. Supporting this hypothesis is a study that screened apparently healthy cats by echocardiography and ECG, which found HCM in 14.7 percent of the population. This data more closely resembles the high number of asymptomatic human HCM cases \[[@R61],[@R62]\]. 

Despite the discrepancy of clinical manifestations, the morphological differences of human and feline HCM are minimal \[[@R67],[@R68]\]. This fact supports the proposal that HCM is basically the same disease in humans and cats \[[@R67]\]. Feline HCM is diagnosed echocardiographically in cats with left ventricular diastolic wall thickness that exceeds 6 mm ([Figure 3](#F3){ref-type="fig"}) \[[@R69]\]. LVH can be asymmetric and it is often seen in the LV anterior wall and papillary muscles. Left atrial chamber size is often enlarged, but it is not an intrinsic feature of HCM \[[@R70]\]. LVOTO secondary to SAM is frequently identified with feline HCM as in human HCM ([Figure 2](#F2){ref-type="fig"}) \[[@R62]\]. Systolic function (e.g., ejection fraction) of the left ventricle is usually normal or hyperdynamic, although progressive reduction in systolic function is noted in some HCM cats presumably secondary to myocardial fibrosis and/or ischemia \[[@R71]\]. 

Approximately 30 percent of human HCM cases are associated with LVOTO at rest and the presence of LVOTO at rest is associated with poorer outcome and higher risk of SD \[[@R72]\]. It is possible that LVOTO may be responsible for elevating ventricular and atrial filling pressures, reducing coronary perfusion, and therefore inducing development of subsequent ischemia and myocardial fibrosis. In cats with HCM, the prevalence of LVOTO is as high as 67 percent \[[@R69]\]. This is considerably higher than observed in human HCM patients \[[@R25]\]. Notably, when humans with HCM are assessed immediately after exercise, the proportion of the HCM cases that demonstrate LVOTO exceeds 60 percent \[[@R15],[@R25]\]. Therefore, the high prevalence of SAM in cats might reflect sympathetic activation associated with a hospital visit because SAM and LVOTO are clearly dependent on physiological state. Interestingly, a few retrospective studies reported that feline HCM with LVOTO is associated with lower mortality than those without LVOTO \[[@R65],[@R69]\]. The effect of LVOTO on morbidity and mortality in cats is thus unclear. The better outcomes with LVOTO in feline HCM may be simply a reflection that these cats are evaluated earlier in the course of disease due to their frequent development of a significant heart murmur.

As in humans, feline HCM is also an inherited disease with autosomal dominant pattern and incomplete penetrance. In 2005, the first genetic mutation associated with feline HCM was identified in the *MYBPC3* gene of Maine Coon cats \[[@R4]\]. Shortly after, a second mutation in the same gene but at a difference locus was also identified in Ragdoll cats \[[@R5]\]. Among these mutations, the A31P missense mutation in *MYBPC3* gene is the most studied and present in approximately 30 to 40 percent of Maine Coon cats \[[@R30]\]. Young male cats are overrepresented for the development of HCM while female Maine Coon cats tend to develop HCM later in their life with milder clinical signs than male respectively \[[@R73]\].

Maine Coon cats with a heterozygous A31P mutation status often do not develop disease or manifest reduced clinical severity of HCM, demonstrating low and incomplete penetrance (6 percent). Conversely, most homozygous cats develop classical echocardiographic changes of HCM earlier in their life with high penetrance \[[@R19],[@R68],[@R74]-[@R76]\]. However, recent study showed Maine Coon cats with the A31P *MYBPC3* heterozygous mutation may have significantly altered cardiac function even if they do not develop clear morphological changes characteristic of HCM. In one study, Maine Coon cats heterozygous for the A31P mutation in *MYBPC3* gene without obvious clinical signs had impaired diastolic function diagnosed based on 2D and tissue Doppler images \[[@R76]\]. Similar findings are noted in Ragdoll cats with the R820W missense mutation in *MYBPC3* \[[@R77]\]. Overall homozygous mutations in *MYBPC3* are associated with higher chance of developing physiological and functional abnormalities due to HCM, while heterozygous cats for either mutation are associated with a lower chance of developing HCM related changes \[[@R74],[@R75]\]. To date, true longitudinal studies are rare in feline HCM and thus more research is needed to firmly determine disease penetrance and expressivity. 

Findings of these major mutations in Maine Coon and Ragdoll cats were led by the identification of similar mutations in human HCM patients and feline candidate gene sequencing \[[@R78]\]. It is likely that additional genes will be identified in cats with HCM, and these may be distinct from the genes or mutations already known in human HCM patients. Thus far, the identified genetic mutations associated with HCM in cats are breed specific and represent only a small fraction of the reported feline HCM cases. The improved annotation of the feline genome has revolutionized the ability to utilize high throughput technologies in the search for causative HCM variants in cats. With the recently published estimates of 14.7 percent of mixed breed cats harboring subclinical HCM, genetic discovery is likely to increase dramatically in the coming years \[[@R60]\]. 

Plasma cTnI and cTnT concentrations are significantly higher in cats with HCM compared to healthy cats, and even higher with CHF than without CHF due to HCM \[[@R79],[@R80]\]. A recent study however failed to show correlation between changes in troponin concentration and the severity of feline HCM \[[@R80]\]. Natriuretic peptides including NTproBNP and NTproANP have also been investigated in feline HCM, and found to be significantly elevated in HCM affected cats \[[@R81]\]. Notably, elevation of NTproBNP is also observed in cats with asymptomatic HCM and thus might be useful as a screening tool to identity high-risk patients \[[@R82]\]. However, as in cTnI and cTnT, only weak correlations between NTproBNP concentrations and the severity of LVH were noted. This contrasts with human HCM where plasma NTproBNP as well as cTnI and cTnI concentrations are strongly correlated with the severity of disease \[[@R82]\]. 

Hypertrophic Cardiomyopathy in Non-human Primate Models {#s7}
=======================================================

Until recently, few case reports of SD in association with LVH were documented in several non-human primates such as captive chimpanzees (*Pan troglodytes*), captive western lowland gorillas (*Gorilla gorilla gorilla*), and owl monkeys (*aotus spp.*) \[[@R83],[@R84]\]. Naturally-occurring LVH with a high rate of SD has been identified and recently reported in captive rhesus macaques. They present clinical and pathologic manifestations resembling HCM in humans \[[@R6],[@R85]\]. Pedigree analysis in this cohort suggested that LVH in rhesus macaques is an inherited disease as in human and feline HCM, and is dominated by founder effects \[[@R7],[@R85]\]. The LVH in rhesus macaques is often symmetric demonstrating both LV posterior and anterior wall thickening with occasionally hypertrophied papillary muscle ([Figure 1](#F1){ref-type="fig"}) \[[@R6],[@R85]\]. These changes were accompanied by a significant reduction of the LV chamber size. Interestingly, unlike human and feline HCM, the histologic lesions of LVH in rhesus macaques lack the classical myocyte disarray, significant myocardial fibrosis, and intramural coronary arterial wall abnormalities. These histological discrepancies may imply that there are pathologic and genetic differences between HCM in humans and rhesus macaques. Nonetheless, disorganized myocyte architecture can be seen in regions with normal to mildly thickened myocardium in human HCM calling into question the specificity and importance of this lesion \[[@R86]\]. This pattern challenges the ideas that the degree of LVH is related to the degree of disorganized myocyte architecture, which is thought to be associated with the degree of clinical manifestation. In fact, as in human patients with HCM, SD remains the primary clinical manifestation of LVH in rhesus macaques, and this similarity suggests that investigating LVH in rhesus macaques may be worthwhile in determining the associations among the histological change, clinical manifestations, and genetic influences. 

The only clinical presentation described thus far with LVH in rhesus macaques is SD, with the diagnosis of LVH made by postmortem examination. Echocardiographic screening of family members also demonstrated a high prevalence of LVH, diastolic dysfunction and mitral regurgitation in rhesus macaques genetically related to LVH-affected individuals that died suddenly ([Figure 3](#F3){ref-type="fig"}). cTnI was also measured in LVH-affected and healthy rhesus macaques, but no significant difference was noted between these groups \[[@R6]\]. No significant difference in the overall incidence of LVH between males and female rhesus macaques was noted, while the male rhesus macaques with LVH had a higher rate of SD than female rhesus macaques with LVH \[[@R20],[@R85]\]. These findings may be influenced by social and behavioral differences between male and female rhesus macaques. The male macaques had physiological activity somewhat similar to young athletes who more commonly develop SD due to HCM. In rhesus macaques with LVH, no direct mechanisms of SD has been determined although it has been speculated to be due to ventricular arrhythmias as in human patients with HCM \[[@R47]\]. Investigation into the possible causative mutation and phenotypic entities of LVH in rhesus macaques is underway. This new animal model of HCM is exciting and may represent the most direct translational approach to the study of human HCM. Continued phenotypic and genotypic investigations are essential to establish this HCM model in non-human primates. 

Hypertrophic Cardiomyopathy in Other Species (rabbits, fish, pigs, dogs)  {#s8}
=========================================================================

Rabbits have advantages for studying human cardiovascular disease due to their cardiovascular system closely resembling that of humans, when compared to murine models \[[@R87]\]. This is especially true regarding calcium ion handling during contraction cycle and an altered calcium ion flux during heart failure \[[@R88]\]. Rabbit myosin composition more closely resembles the human heart than murine heart, which is comprised of mainly alpha myosin. Transgenic rabbit models with mutations in beta-*MYH* or cTnI were previously created and produced severe defects including LVH and a high incidence of premature death \[[@R89],[@R90]\]. 

Zebrafish are another important animal model for HCM. These fish are an especially important model for studying cardiac development, due to the external development of the heart, enabling the assessment of cardiac gene function during embryologic formation. Also, zebrafish embryos with HCM-associated gene modifications can continue to grow for several days since they initially do not rely on the cardiovascular system for oxygen delivery. Finally, despite the simpler structure of the zebrafish heart compared to mammals, the essential genes responsible for heart development are largely conserved \[[@R91]\]. One research group developed a zebrafish model of a *TNNT2* human mutation to assess its impact during heart development. They discovered that the *TNNT2* mutation in zebrafish led to a similar phenotype with matching myocardial hypertrophy pathways. Also, they observed that the embryonic hearts developed cardiomyocyte hyperplasia. This led them to conclude that sarcomeric mutations can impact the cardiomyocytes much earlier than previously understood and that despite similar transcriptional responses they possess clear differences when compared to adult hearts \[[@R92]\].

Naturally occurring heritable HCM was also reported in pigs, and many of the pathologic and echocardiographic characteristics of HCM in pigs closely resemble those in humans with HCM \[[@R93]-[@R95]\]. Other structural and biochemical features in pigs are similar to those in other species, including increased amounts of collagen matrix, abnormalities in intramural coronary arteries, and decreased calcium ATPase activity within the LV \[[@R96]-[@R98]\]. Although the HCM-affected pig is a potential model for studying the pathogenesis of HCM-associated disease and assisting in design of therapeutic interventions, genetic and heritability investigations are not fully characterized and further phenotypic and genotypic studies are required. 

HCM is a rare disease in dogs, but there are limited reports characterizing naturally occurring HCM in dogs with similar histopathologic and clinical abnormalities to feline and human HCM \[[@R68]\]. In the small number of reports on canine HCM some breed predilection was proposed which included Rottweilers, Dalmatians, and various other breeds \[[@R68],[@R99]\]. The infrequency of this condition in dogs renders it impossible to draw meaningful conclusions at this time. 

Beyond the Genetic Mutations {#s9}
============================

Many mutations are found to be associated with HCM in humans, but the molecular pathways resulting in the broad spectrum of HCM phenotypes remain unclear. Understanding these mechanisms are the cornerstone of developing novel HCM therapies that aim to modify the natural course of this disease. Several hypotheses explaining the development of the HCM phenotype are supported to varying degrees in the literature and underscore the complex pathophysiology of this condition. The initially proposed hypothesis was that mutations results in a decreased myocardial contractility and subsequent LVH due to compensatory mechanisms \[[@R100]\]. However, some studies identified gain-of-function mutations with increased myocardial contractility, suggesting decreased myocardial contractility is an incomplete explanation of phenotypic HCM \[[@R101],[@R102]\].

Altered myocardial calcium ion sensitivity is another mechanism proposed for the various phenotypes of HCM. Genetic mutations in myofilament proteins increase the sensitivity of calcium ions, alter calcium ion handling, and change the calcium reuptake at the sarcoplasmic reticulum \[[@R103]\]. This may result in development of HCM-associated cardiac arrhythmias which can be reduced or eliminated through the administration of calcium channel blocking drugs \[[@R104]\]. This effect was noted even in the absence of LVH, which indicates that arrhythmias with HCM are not entirely secondary to structural abnormalities.

Diastolic dysfunction and cardiac arrhythmias observed with HCM are commonly attributed to myocardial fibrosis, left ventricular hypertrophy, and myocyte disarray \[[@R105],[@R106]\]. The molecular mechanisms leading to the development of myocardial fibrosis in HCM is incompletely understood and largely attributed to ongoing myocardial apoptosis, microvascular ischemia, or fibroblast proliferation linked to sarcomeric mutations \[[@R9],[@R107]\]. In human HCM patients, severity of myocardial fibrosis has been identified as an independent risk factor for adverse outcomes \[[@R108]\]. Significant myocardial fibrosis however is not a major feature of naturally occurring LVH of other species, such as rhesus macaques with SD \[[@R85]\]. Further investigations are thus necessary to better understand the role of myocardial fibrosis and its relationship to clinical symptoms of HCM in humans and other animals.

Several studies have reported that myocardial dysfunction sometime seen in HCM patients was due to a combination of inefficient ATP utilization at the sarcomere concurrent with increased energy demand \[[@R109]\]. One study showed that myocardial contraction cycles were faster in mutated sarcomeres necessitating a greater energy demand due to their inefficient energy utilization \[[@R110]\]. This effect might partially explain diastolic dysfunction and ventricular arrhythmias in HCM patients \[[@R111]\]. Recently, a novel small molecule, MYK-461, was tested in mouse models of HCM and found to reduce contractility by decreasing ATPase activity of the cardiac myosin heavy chain, and thus lower myocardial energy demands through more efficient utilization of ATP \[[@R112]\]. This effect is also demonstrated in feline models with HCM \[[@R113]\]. MYK-461 was further shown to suppress the development of LVH, myocyte disarray and fibrosis in genetic mouse models of HCM \[[@R112]\]. The results of this novel therapy support the role of inefficient ATP utilization in HCM. It also indicates that hyperdynamic contraction may be a key component of HCM pathophysiology, and that novel inhibitors of myocardial contraction, such as MYK-461, may represent promising therapeutic options for HCM in humans and other species. 

Conclusions and Outlook {#s10}
=======================

HCM is a devastating heritable condition in humans affecting 1 in 500 and frequently leading to SD in young athletes and HF in older individuals. Past research has revealed a variety of genotypic and phenotypic information regarding HCM, which has been extensively tested and described through the use of animal models. Analysis of mouse HCM models indicate phenotypic and genotypic interactions that suggest specific mutations result in specific disease phenotypes. However, there are significant limitations to directly translate these findings into human HCM due to significant cardiac and hemodynamic differences between the two species. Naturally occurring large animal models of HCM are necessary to bridge this divide. Naturally occurring HCM in cats is morphologically and histologically similar to human HCM. Moreover, similar mutations in association with HCM in some breeds of cats have been also identified in human HCM patients. These findings indicate that feline HCM research may result in translational advancements and better define the complex genotype-phenotype relationships that limit clinical advancements in human HCM therapy. Recent investigation and development of a non-human primate model of naturally occurring LVH in rhesus macaques may also eventually shed light on the complex molecular pathogenesis of this condition and help to advance the diagnostic and therapeutic approaches to HCM. The constant evolution of new technologies, such as the availability of low-cost next generation sequencing and push towards precision medicine may also guide our understanding of genotype-phenotype relationships in this complex disease. The description of new animal models and development of novel therapeutics rooted in the molecular pathogenesis of this disease offer promise for the future diagnosis and management of HCM across many species. 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AF

:   atrial fibrillation

BNP

:   brain natriuretic peptide

CMR

:   cardiovascular magnetic resonance image

ECG

:   electrocardiography

HCM

:   hypertrophic cardiomyopathy

HF

:   heart failure

LVH

:   left ventricular hypertrophy

LV

:   left ventricle

LVOTO

:   left ventricular outflow tract obstruction

MYBPC

:   Myosin-binding protein C

MYH

:   myosin heavy chain

SAM

:   systolic anterior motion

SD

:   sudden death

cTnC

:   cardiac troponin C

cTnI

:   cardiac troponin I

cTnT

:   cardiac troponin T

2D

:   two-dimensional

###### Identified genetic mutations in association with HCM in various species.

  **Species**      **Genes**                                                       **References**
  ---------------- --------------------------------------------------------------- -------------------------------------
  Human            *ACTC1* (Actin, Alpha, Cardiac Muscle 1)                        \[[@R114]-[@R116]\] 
                   *ACTN2* (Actin Alpha 2)                                         \[[@R117],[@R118]\] 
                   *CALR3* (Calreticulin 3)                                        \[[@R119]\]
                   *CSRP3* (Cysteine and Glycine Rich Protein 3)                   \[[@R37],[@R38]\]
                   *JPH2* (Junctophilin 2)                                         \[[@R120],[@R121]\] 
                   *MYBPC3* (Myosin Binding Protein C, Cardiac)                    \[[@R122]-[@R130]\]
                   *MYH7* (Myosin Heavy Chain 7)                                   \[[@R131]-[@R139]\]
                   *MYL2* (Myosin Light Chain 2)                                   \[[@R140]-[@R142]\] 
                   *MYL3* (Myosin Light Chain 3)                                   \[[@R140],[@R143],[@R144]\] 
                   *MYOM1* (Myomesin-1)                                            \[[@R41]\] 
                   *MYOZ2* (Myozenin 2)                                            \[[@R40],[@R145]\]
                   *NEXN* (Nexilin F-actin Binding Protein)                        \[[@R146]\]
                   *PLN* (Phospholamban)                                           \[[@R147],[@R148]\]
                   *PRKAG2* (Protein Kinase AMP-Activated Catalytic Subunit α2)    \[[@R149]-[@R152]\]
                   *TCAP* (Titin-Cap)                                              \[[@R39],[@R153]\]
                   *TNNI3* (Troponin I3, Cardiac Type)                             \[[@R34],[@R115],[@R154],[@R155]\]
                   *TNNT2* (Troponin T2, Cardiac Type)                             \[[@R35],[@R100],[@R156]-[@R158]\] 
                   *TPM1* (Tropomyosin 1)                                          \[[@R156],[@R159],[@R160]\] 
                   *TTN* (Titin)                                                   \[[@R36],[@R161]\]
                   *VCL* (Vinculin)                                                \[[@R162]\]
  Cat              *MYBPC3* (Myosin Binding Protein C, Cardiac)                    \[[@R4],[@R5],[@R163]\]
  Pig              Not yet defined                                                 
  Dog              Not yet defined                                                 
  Rhesus macaque   Not yet defined                                                 Under investigation

![Gross necropsy images of (**A**) cat and (**B**) rhesus macaque with severe left ventricular hypertrophy. Hearts were transversely transected midway between the apex and base of the hearts (Gross necropsy image of rhesus macaque courtesy of R. Reader).](yjbm_90_3_433_g01){#F1}

![2-Dimensional right parasternal left ventricular outflow tract view in systole with color-Doppler showing left ventricular outflow tract obstruction secondary to systolic anterior motion of the mitral valve in a cat with HCM. Mitral valve regurgitation is also evident.](yjbm_90_3_433_g02){#F2}

![Right parasternal short axis imaging at the level of the papillary muscle in a normal rhesus macaque (**A** and **B**) and a rhesus macaque with severe left ventricular hypertrophy consistent with HCM (**C** and **D**). The images are presented as systole (**B** and **D**) and diastole (**A** and **C**).](yjbm_90_3_433_g03){#F3}
